Aim: To compare sensor accuracy (Medtronic Enlite2®) after a subcutaneous (s.c) injection of low-dose glucagon near vs. remote from sensor site.
Methods: Twelve adults with type 1 diabetes wore two continuous glucose monitors (CGMglucagon and CGMctrl) placed on each side of the abdomen during two overnight in-clinic visits. CGM values were compared with YSI values. Four hours prior to visit end, a s.c 100 µg glucagon injection was administered 0.2 cm next to the CGMglucagon, and 2 hours later another bolus was injected next to the same sensor. Afterwards, CGM performance was compared with 3-day self-monitoring of blood glucose (SMBG) in free-living conditions.
Results: Using YSI as comparator, the overall median absolute relative difference (MARD) for CGMglucagon (N=772) was 17.9% and 14.7% for CGMctrl (N=1352), p=0.15. The percentage of values in zone A+B of Clarke Error Grid Analysis was 96.9% for YSI-CGMglucagon and 97.0% for YSI-CGMctrl, p=0.98. With respect to SMBG, the MARD for CGMglucagon (N=319) was 19.3% and 13.8% for CGMctrl (N=464), p=0.02. The percentage of values in zone A+B for SMBG-CGMglucagon was 94.7% compared to 97.2% for SMBG-CGMctrl, p=0.77. The precision absolute relative deviation between sensors was 16.0%.
C. Laugesen: None. S. Schmidt: Speaker's Bureau; Self; Novo Nordisk A/S. R. Tetzschner: None. K. Nørgaard: Advisory Panel; Self; Abbott, Medtronic, Novo Nordisk A/S. Speaker's Bureau; Self; Bayer US, Medtronic, Roche Diabetes Care, Rubin Medical, Sanofi, Zealand Pharma A/S. Stock/Shareholder; Self; Novo Nordisk A/S. A. Ranjan: None.
Danish Diabetes Academy